Literature DB >> 1473438

Pharmaceutical characterization of corticosteroid suppository treatment for ulcerative colitis.

S Sadahiro1, Z Ito, T Iijima, M Noguchi, K Hosoi.   

Abstract

The dose and method of administration of a corticosteroid given for the treatment of patients with ulcerative colitis are determined according to the range of the diseased area and its severity. In this study, we prepared a hydrophilic suppository consisting of water-soluble prednisolone sodium succinate (PSL-SS) and a hydrophilic base, polyethylene glycol (PEG), and a hydrophobic suppository consisting of water-insoluble prednisolone (PSL) and a hydrophobic base, Witepsol (WT). We determined the spread of the drugs after intrarectal administration and their therapeutic effect. When rats received the hydrophilic suppository, the drug spread farther oral than when they received the hydrophobic suppository. Moreover, more than half of the PSL-SS recovered was observed to have changed into PSL. A therapeutic effect on the colitis induced in rats by acetic acid was noted in the area up to 10 cm from the anus in the case of the hydrophilic suppository, while the effect of the hydrophobic suppository was seen only in the area up to 2.5 cm from the anus. In patients with ulcerative colitis, the hydrophilic suppository showed retrograde spread to a site 34.4 +/- 5.3 cm from the anus, while the hydrophobic suppository spread to a site 19.0 +/- 2.4 cm from the anus. These results suggest that a hydrophobic suppository should be used for patients in whom inflammation is confined to the rectum, and a hydrophilic suppository used for patients in whom inflammation reaches the rectum and the middle part of the sigmoid colon.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473438     DOI: 10.1007/bf01308085

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  On the mechanism of intestinal absorption of drugs.

Authors:  C A HOGBEN; D J TOCCO; B B BRODIE; L S SCHANKER
Journal:  J Pharmacol Exp Ther       Date:  1959-04       Impact factor: 4.030

2.  Intrarectal treatment of 100 cases of ulcerative colitis with prednisolone-21-phosphate enemata.

Authors:  S G MATTS
Journal:  Br Med J       Date:  1961-01-21

3.  Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial.

Authors:  S C TRUELOVE; M H HAMBLING
Journal:  Br Med J       Date:  1958-11-01

4.  Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium; a controlled trial employing restricted sequential analysis.

Authors:  G WATKINSON
Journal:  Br Med J       Date:  1958-11-01

5.  Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium.

Authors:  S C TRUELOVE
Journal:  Br Med J       Date:  1957-06-22

6.  A study of suppository bases using radioiodine to compare the rate of absorption from rectal suppositories administered to rats.

Authors:  C F PETERSON; C O LEE; J E CHRISTIAN
Journal:  J Am Pharm Assoc Am Pharm Assoc       Date:  1953-12

7.  Liquid chromatographic determination of theophylline concentration with syringe-type minicolumns for direct plasma injection.

Authors:  M Homma; K Oka; N Takahashi
Journal:  Anal Chem       Date:  1989-04-01       Impact factor: 6.986

8.  Adjunctive use of a steroid rectal foam in the treatment of ulcerative colitis.

Authors:  N D Scherl; B A Scherl
Journal:  Dis Colon Rectum       Date:  1973 Mar-Apr       Impact factor: 4.585

9.  Disposition of radiolabelled suppositories in humans.

Authors:  M Jay; R M Beihn; G A Digenis; F H Deland; L Caldwell; A R Mlodozeniec
Journal:  J Pharm Pharmacol       Date:  1985-04       Impact factor: 3.765

10.  Experimental production of diffuse colitis in rats.

Authors:  B R MacPherson; C J Pfeiffer
Journal:  Digestion       Date:  1978       Impact factor: 3.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.